Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers

被引：69

作者：

Kotsopoulos, J

Lubinski, J

Lynch, HT

Neuhausen, SL

Ghadirian, P

Isaacs, C

Weber, B

Kim-Sing, C

Foulkes, WD

Gershoni-Baruch, R

Ainsworth, P

Friedman, E

Daly, M

Garber, JE

Karlan, B

Olopade, OI

Tung, N

Saal, HM

Eisen, A

Osborne, M

Olsson, H

Gilchrist, D

Sun, P

Narod, SA

机构：

[1] Univ Toronto, Womens Coll Hosp, Ctr Res Womens Hlth, Toronto, ON M5G 1N8, Canada

[2] Univ Toronto, Dept Nutr Sci, Toronto, ON, Canada

[3] Pomeranian Med Univ, Hereditary Canc Ctr, Szczecin, Poland

[4] Creighton Univ, Sch Med, Dept Prevent Med & Publ Hlth, Omaha, NE USA

[5] Univ Calif Irvine, Dept Med, Div Epidemiol, Irvine, CA 92717 USA

[6] CHU Montreal, CHUM Hotel Dieu, Res Ctr, Epidemiol Res Unit,Dept Nutr,Fac Med, Montreal, PQ, Canada

[7] Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Washington, DC 20007 USA

[8] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada

[9] Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA

[10] McGill Univ, Dept Med, Montreal, PQ, Canada

[11] McGill Univ, Dept Human Genet, Montreal, PQ, Canada

[12] McGill Univ, Dept Oncol, Montreal, PQ, Canada

[13] Rambam Med Ctr, Inst Genet, Haifa, Israel

[14] London Reg Canc Ctr, London, ON N6A 4L6, Canada

[15] Chaim Sheba Med Ctr, Suzanne Levy Gertner Oncogenet Unit, IL-52621 Tel Hashomer, Israel

[16] Fox Chase Canc Ctr, Div Populat Sci, Philadelphia, PA 19111 USA

[17] Dana Farber Canc Inst, Boston, MA 02115 USA

[18] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA

[19] Univ Chicago, Ctr Clin Canc Genet, Chicago, IL 60637 USA

[20] Beth Israel Med Ctr, Boston, MA USA

[21] Childrens Hosp Med Ctr, Div Human Genet, Hereditary Canc Program, Cincinnati, OH USA

[22] Toronto Sunnybrook Reg Canc Ctr, Toronto, ON, Canada

[23] Strang Canc Prevent Ctr, New York, NY USA

[24] Univ Lund Hosp, Dept Oncol, Jubileum Inst, S-22185 Lund, Sweden

[25] WCM Univ Alberta, Edmonton, AB, Canada

来源：

CANCER CAUSES & CONTROL | 2005年 / 16卷 / 06期

关键词：

BRCA1; BRCA2; age at menarche; breast cancer; case-control study; reproductive modifiers;

D O I：

10.1007/s10552-005-1724-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Age at menarche is a strong and consistent predictor of breast cancer risk in the general population, but has not been well studied in women with a family history of breast cancer. We conducted this study to examine whether the presence of a deleterious BRCA1 or BRCA2 mutation influences age at menarche and to investigate whether or not there is an association between age at menarche and the risk of breast cancer in BRCA1 or BRCA2 mutation carriers. The presence of a deleterious BRCA1 or BRCA2 mutation did not appear to influence a woman's age at menarche. A matched case-control study was conducted on 1311 pairs of women who have been identified to be carriers of a deleterious mutation in either the BRCA1 (n = 945 pairs) or the BRCA2 gene (n = 366 pairs). Information about age at menarche was derived from a questionnaire routinely administered to carriers of a mutation in either gene. Among women who carried a deleterious BRCA1 mutation, age at menarche was inversely associated with the risk of breast cancer (p trend = 0.0002). This association was not observed among BRCA2 mutation carriers (p trend = 0.49). Compared with BRCA1 carriers whose age at menarche was <= 11 years, women with a menarcheal age between 14 and 15 years old had a 54% reduction in risk (OR = 0.46; 95% CI 0.30-0.69). This study implicates early age at menarche as a determinant of breast cancer among women with a BRCA1 mutation.

引用

页码：667 / 674

页数：8

共 53 条

[1]

[Anonymous], COMPLEXITY

[2] BRCA1 induces antioxidant gene expression and resistance to oxidative stress [J].